image
Healthcare - Drug Manufacturers - General - NYSE - DK
$ 59.91
0.43 %
$ 293 B
Market Cap
17.06
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one NVO stock under the worst case scenario is HIDDEN Compared to the current market price of 59.9 USD, Novo Nordisk A/S is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one NVO stock under the base case scenario is HIDDEN Compared to the current market price of 59.9 USD, Novo Nordisk A/S is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one NVO stock under the best case scenario is HIDDEN Compared to the current market price of 59.9 USD, Novo Nordisk A/S is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart NVO

image
$120.0$120.0$110.0$110.0$100.0$100.0$90.0$90.0$80.0$80.0$70.0$70.0$60.0$60.0$50.0$50.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
290 B REVENUE
25.03%
128 B OPERATING INCOME
25.12%
101 B NET INCOME
20.68%
121 B OPERATING CASH FLOW
11.07%
-129 B INVESTING CASH FLOW
-193.66%
8.74 B FINANCING CASH FLOW
113.83%
85.7 B REVENUE
20.15%
36.7 B OPERATING INCOME
8.30%
28.2 B NET INCOME
3.40%
12.3 B OPERATING CASH FLOW
-71.95%
-91.2 B INVESTING CASH FLOW
-336.36%
36.8 B FINANCING CASH FLOW
300.18%
Balance Sheet Novo Nordisk A/S
image
Current Assets 161 B
Cash & Short-Term Investments 26.3 B
Receivables 87.4 B
Other Current Assets 47.2 B
Non-Current Assets 305 B
Long-Term Investments 2.68 B
PP&E 162 B
Other Non-Current Assets 140 B
5.65 %18.77 %10.13 %34.88 %30.00 %Total Assets$465.8b
Current Liabilities 218 B
Accounts Payable 28.8 B
Short-Term Debt 13.1 B
Other Current Liabilities 176 B
Non-Current Liabilities 105 B
Long-Term Debt 89.7 B
Other Non-Current Liabilities 15.1 B
8.95 %4.07 %54.47 %27.82 %4.69 %Total Liabilities$322.3b
EFFICIENCY
Earnings Waterfall Novo Nordisk A/S
image
Revenue 290 B
Cost Of Revenue 44.5 B
Gross Profit 246 B
Operating Expenses 118 B
Operating Income 128 B
Other Expenses 27.4 B
Net Income 101 B
300b300b250b250b200b200b150b150b100b100b50b50b00290b(45b)246b(118b)128b(27b)101bRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
84.67% GROSS MARGIN
84.67%
44.19% OPERATING MARGIN
44.19%
34.78% NET MARGIN
34.78%
70.38% ROE
70.38%
21.68% ROA
21.68%
38.99% ROIC
38.99%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Novo Nordisk A/S
image
80b80b70b70b60b60b50b50b40b40b30b30b20b20b10b10b0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 101 B
Depreciation & Amortization 8.54 B
Capital Expenditures -51.3 B
Stock-Based Compensation 2.29 B
Change in Working Capital -12 B
Others 3.05 B
Free Cash Flow 69.7 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Novo Nordisk A/S
image
Wall Street analysts predict an average 1-year price target for NVO of $158 , with forecasts ranging from a low of $156 to a high of $160 .
NVO Lowest Price Target Wall Street Target
156 USD 160.39%
NVO Average Price Target Wall Street Target
158 USD 164.40%
NVO Highest Price Target Wall Street Target
160 USD 167.07%
Price
Max Price Target
Min Price Target
Average Price Target
160160140140120120100100808060604040Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
1.1 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
1.200001.200001.000001.000000.800000.800000.600000.600000.400000.400000.200000.200000.000000.000000.380.4820.33150.3350.39450.782610.47450.5180.59450.929851.099210.22350.600.2370.720.23350.570.22450.560.2590.650.27851.060.2920.770.4420.960.512641.110.931.102015201520162016201720172018201820192019202020202021202120222022202320232024202420252025
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 16
6. Ownership
Insider Ownership Novo Nordisk A/S
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Why Novo Nordisk Stock Popped Today Novo Nordisk (NVO 2.71%), the Danish drugmaker that's been riding high ever since it began putting out Ozempic and Wegovy GLP-1 injectables for treatment of diabetes and weight loss, got another shot in the arm yesterday -- one that helped the stock dodge the market downturn entirely and end the day somewhat in the green. The same news that helped Novo stock out yesterday, moreover, is today turning into solid gains as Novo Nordisk stock rises 2.5% through 11 a.m. fool.com - 1 week ago
Eli Lilly, Vertex, AbbVie and More Pharma Stocks to Own as Tariffs Loom Trump's tariff policy is the latest uncertainty to plague the pharmaceutical sector. barrons.com - 1 week ago
Novo Nordisk: Be Greedy When Others Are Fearful Novo Nordisk is a high-quality biopharma company with a strong diabetes franchise and a booming obesity drug segment, making it an attractive growth play. Following a 50% drop from recent highs, NVO trades at a significant discount compared to historical valuations, presenting a buying opportunity. The company's diverse portfolio, including diabetes, obesity, and rare diseases, ensures robust growth and reduces reliance on any single product. seekingalpha.com - 1 week ago
Think It's Too Late to Buy Novo Nordisk? Here's the Biggest Reason Why There's Still Time. Almost unarguably, the most significant story in our time with the pharmaceutical industry is the emergence and sharp rise of GLP-1 obesity drugs. Front and center of this is Novo Nordisk (NVO 0.48%), the once-obscure Danish company that earned the first U.S. Food and Drug Administration (FDA) approval for such treatments with its Wegovy back in mid-2021. fool.com - 1 week ago
Novo Nordisk Shares Fall After Data From New Eli Lilly Pill Shares fell after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant's blockbuster shots. wsj.com - 1 week ago
Down 60%, Is This Growth Stock Too Cheap to Ignore? In this video, I will cover recent updates regarding Novo Nordisk (NVO 0.48%). Watch the short video to learn more, consider subscribing, and click the special offer link below. fool.com - 1 week ago
Is Novo Nordisk falling behind Eli Lilly in the weight-loss drug race? Danish drugmaker Novo Nordisk A/S (CPH: NOVO-B) lost more than 10% last week after its US rival Eli Lilly & Co (NYSE: LLY) reported encouraging Phase 3 data for its oral weight-loss treatment.  Lilly's orforglipron demonstrated “statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines” in the late-stage clinical trial. invezz.com - 1 week ago
Novo Nordisk (NVO) Ascends While Market Falls: Some Facts to Note Novo Nordisk (NVO) closed the most recent trading day at $58.33, moving +0.43% from the previous trading session. zacks.com - 1 week ago
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store. zacks.com - 1 week ago
Down 61%, Is Novo Nordisk Stock Worth Buying on the Dip? Novo Nordisk (NVO -7.78%) stock hit an all-time high of $148.15 in June 2024, marking a remarkable fivefold surge since 2019. Yet the stock has since plummeted 61% from its peak value. fool.com - 1 week ago
LLY, NVO and AMGN Forecast – Pharma Stocks to Open Mixed The three pharma stocks in this analysis all look a bit mixed in the premarket, after seeing some momentum late last week. This is especially true with LLY, as you will see on the charts. fxempire.com - 1 week ago
Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (April 2025) Among all the weight loss drugs, Ozempic has become a phenomenon. With as much as $17 billion in sales in 2024, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). 247wallst.com - 1 week ago
8. Profile Summary

Novo Nordisk A/S NVO

image
COUNTRY DK
INDUSTRY Drug Manufacturers - General
MARKET CAP $ 293 B
Dividend Yield 0.00%
Description Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Contact Novo Alle 1, Bagsvaerd, 2880 https://www.novonordisk.com
IPO Date April 30, 1981
Employees 76302
Officers Mr. Lars Fruergaard Jorgensen President, Chief Executive Officer & Member of Management Board Mr. Karsten Munk Knudsen Executive Vice President, Chief Financial Officer & Member of the Management Board Dr. Marcus Schindler Ph.D. EVice President of Research & Early Development, Chief Scientific Officer & Member of the Management Board Mr. Ludovic Helfgott Executive Vice President of Product & Portfolio Strategy and Member of Management Board Ms. Tania Sabroe EVice President of People, Organisation and Communication & Member of Management Board Mr. David S. Moore Executive Vice President of US Operations & Global Business Development and Member of Management Board Jacob Martin Wiborg Rode Head of Investor Relations Dr. Martin Holst Lange Executive Vice President of Development & Member of the Management Board Mr. Henrik Ehlers Wulff Executive Vice President of Product Supply, Quality & IT and Member of the Management Board Mr. Maziar Mike Doustdar Executive Vice President of International Operations & Member of the Management Board